Financial Contrast: Oncocyte (IMDX) vs. The Competition

Oncocyte (NASDAQ:IMDX) is one of 855 public companies in the “Biotechnology” industry, but how does it weigh in compared to its peers? We will compare Oncocyte to similar companies based on the strength of its dividends, valuation, profitability, earnings, risk, institutional ownership and analyst recommendations.

Profitability

This table compares Oncocyte and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Oncocyte	-2,955.63%	N/A	-107.52%
Oncocyte Competitors	-9,461.75%	-127.85%	-33.14%

Risk & Volatility

Oncocyte has a beta of 1.8, meaning that its share price is 80% more volatile than the S&P 500. Comparatively, Oncocyte’s peers have a beta of 1.10, meaning that their average share price is 10% more volatile than the S&P 500.

Institutional & Insider Ownership

55.3% of Oncocyte shares are held by institutional investors. Comparatively, 48.1% of shares of all “Biotechnology” companies are held by institutional investors. 2.2% of Oncocyte shares are held by company insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of current ratings for Oncocyte and its peers, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncocyte	1	0	2	0	2.33
Oncocyte Competitors	9448	14910	44694	1513	2.54

Oncocyte presently has a consensus target price of $10.50, suggesting a potential upside of 193.30%. As a group, “Biotechnology” companies have a potential upside of 64.21%. Given Oncocyte’s higher possible upside, research analysts clearly believe Oncocyte is more favorable than its peers.

Valuation & Earnings

This table compares Oncocyte and its peers gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Oncocyte	$4.05 million	-$50.22 million	-2.40
Oncocyte Competitors	$683.71 million	$9.18 million	-11.10

Oncocyte’s peers have higher revenue and earnings than Oncocyte. Oncocyte is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Summary

Oncocyte beats its peers on 7 of the 13 factors compared.

Oncocyte Company Profile

OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.